Mechanisms of Brain Hypoperfusion in AD/ADRD (R01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) solicits applications for projects designed to understand molecular and cellular mechanisms underlying cerebral blood flow reduction in Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD)

Deadlines:

  • Letter of Intent Due Date(s): June 01, 2022

  • Application Due Date: July 01, 2022

RFA-AG-23-014 Expiration Date July 02, 2022

Eligibility

Faculty

Category

Medical
Medical - Basic Science

External Deadline

July 1, 2022